{"id":546812,"date":"2021-06-09T15:00:01","date_gmt":"2021-06-09T15:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=546812"},"modified":"2021-06-09T15:00:01","modified_gmt":"2021-06-09T15:00:01","slug":"follicular-lymphoma-market-is-likely-to-grow-at-a-modest-rate-owing-to-rising-prevalence-and-the-anticipated-launch-of-novel-therapies-by-major-pharmaceutical-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/follicular-lymphoma-market-is-likely-to-grow-at-a-modest-rate-owing-to-rising-prevalence-and-the-anticipated-launch-of-novel-therapies-by-major-pharmaceutical-companies_546812.html","title":{"rendered":"Follicular Lymphoma market is likely to grow at a modest rate, owing to rising prevalence and the anticipated launch of novel therapies by major pharmaceutical companies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1623228372.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Follicular Lymphoma market is likely to grow at a modest rate, owing to rising prevalence and the anticipated launch of novel therapies by major pharmaceutical companies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1623228372.png\" alt=\"Follicular Lymphoma market is likely to grow at a modest rate, owing to rising prevalence and the anticipated launch of novel therapies by major pharmaceutical companies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Follicular Lymphoma Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The expected launch of emerging therapies, as well as an increase in the incidence of Follicular Lymphoma, will drive the Follicular Lymphoma market during the forecasted period (2021\u20132030).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/3049a4efbf4f05e810fdb54de4ace58e.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">&lsquo;Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast &ndash; 2030&#8242;<\/a>&nbsp;<\/strong><span>report from DelveInsight provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as market trends in the US, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Key Highlights from the Follicular Lymphoma Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to Mozas et al (2020) study, &#8220;Patterns of change in treatment, responsiveness, and prognosis in patients with Follicular Lymphoma throughout the previous four decades: a single-center experience,&#8221; <\/span><strong>54 percent<\/strong><span> of Follicular Lymphoma patients were refractory or had relapse\/progression during follow-up.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The incidence of Follicular Lymphoma in Japan was <\/span><strong>2.80 per 100,000<\/strong><span> people, according to a study by Fujishima et al. (2018) titled &#8220;Incidence Rate, Subtype Frequency, and Occurrence Site of Malignant Lymphoma in the Gastrointestinal Tract: Population-Based Analysis in Miyagi, Japan.&#8221;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pipeline therapies in the Follicular Lymphoma market include <\/span><strong>Tazverik(Tazemetostat)<\/strong><span> (Epizyme), <\/span><strong>Abexinostat<\/strong><span> (Xynomic Pharmaceuticals), <\/span><strong>ME-401 <\/strong><span>(MEI Pharma), <\/span><strong>Tisagenlecleucel<\/strong><span> (Novartis Pharmaceuticals), <\/span><span><strong>Parsaclisib<\/strong> <strong>(IBI376)<\/strong><\/span><span> (Innovent Biologics) and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Major companies involved in the Follicular Lymphoma market include <\/span><strong>Epizyme, Xynomic Pharmaceuticals, MEI Pharma, Novartis Pharmaceuticals, Innovent Biologics,<\/strong><span> among others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Learn more by requesting sample @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/follicular-lymphoma-market-insights?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Follicular Lymphoma Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The Follicular Lymphoma market report<\/span><span> also examines existing Follicular Lymphoma treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs in order to gather the best of the prospects and assess the market&#8217;s underlying potential.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Follicular Lymphoma: Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Follicular Lymphoma (FL) is a cancer that affects lymphocytes, which are white blood cells. The cancer is caused by the unregulated division of centrocytes and centroblasts, two types of B-cells. These cells generally reside in the germinal centres of lymphoid tissues such as lymph nodes, where they form follicles (nodular swirls of several types of lymphocytes). FL malignant cells penetrate tissues and create follicular or follicle-like formations. These structures are frequently the cancer&#8217;s most prominent histological feature.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Follicular Lymphoma Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Follicular Lymphoma Total Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Follicular Lymphoma Risk-Specific Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Follicular Lymphoma Stage-Specific Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Follicular Lymphoma Mutation-Specific Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Follicular Lymphoma Refractory\/Relapsed Incident Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Follicular Lymphoma Treatable Cases<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Follicular Lymphoma Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Depending on the severity of the associated symptoms and the rate of cancer growth, there are a variety of treatment options for Follicular Lymphoma. <\/span><span>Chemotherapy, radiation therapy, immunotherapy, and stem cell transplant<\/span><span> are among the therapies used to treat Follicular Lymphoma. Patients with early-stage Follicular Lymphoma (Ann Arbor stages I or II) can get either radiation therapy alone or radiation therapy along with chemotherapy.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Follicular Lymphoma Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Increase in the incidence of Follicular Lymphoma as well as the expected launch of emerging therapies will boost the Follicular Lymphoma market in the forecasted period (2021&ndash;2030).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Tazverik (Tazemetostat) (Epizyme), Abexinostat (Xynomic Pharmaceuticals), ME-401 (MEI Pharma), Tisagenlecleucel (Novartis Pharmaceuticals), Parsaclisib (IBI376) (Innovent Biologics) are some of the most anticipated emerging therapies that are awaiting approval.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Know more about follicular lymphoma @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Follicular Lymphoma Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Follicular Lymphoma Pipeline Therapies and Major Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Tazverik (Tazemetostat): Epizyme<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Abexinostat: Xynomic Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>ME-401: MEI Pharma<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Tisagenlecleucel: Novartis Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Parsaclisib (IBI376): Innovent Biologics<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"64\" \/>\n<col width=\"560\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive Summary of Follicular Lymphoma (FL)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Follicular Lymphoma Market Share at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Follicular Lymphoma Disease Background and Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Follicular Lymphoma Patient journey<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Follicular Lymphoma Epidemiology and Patient Population<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Country Wise: Epidemiology of Follicular Lymphoma<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Follicular Lymphoma Current Treatment and Medical Practices<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Follicular Lymphoma Marketed Drugs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Current Unmet Needs of Follicular Lymphoma<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Follicular Lymphoma Emerging Therapeutics&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Market Size of Follicular Lymphoma (FL)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Region-Wise Market size of Follicular Lymphoma&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Follicular Lymphoma Market Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>SWOT Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Follicular Lymphoma Reimbursement<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Report Methodology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span> DelveInsight Capabilities<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disclaimer<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">CAR T Cell Therapy for Non Hodgkin&rsquo;s Lymphoma Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get comprehensive historical and forecast analysis of <\/span><span>CAR T Cell Therapy for Non Hodgkin&rsquo;s Lymphoma Market<\/span><span>, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><strong>Novartis, Gilead Sciences,&nbsp;<\/strong><span>among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span>&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=follicular-lymphoma-market-is-likely-to-grow-at-a-modest-rate-owing-to-rising-prevalence-and-the-anticipated-launch-of-novel-therapies-by-major-pharmaceutical-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=follicular-lymphoma-market-is-likely-to-grow-at-a-modest-rate-owing-to-rising-prevalence-and-the-anticipated-launch-of-novel-therapies-by-major-pharmaceutical-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Follicular Lymphoma Market The expected launch of emerging therapies, as well as an increase in the incidence of Follicular Lymphoma, will drive the Follicular Lymphoma market during the forecasted period (2021\u20132030). The &lsquo;Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/follicular-lymphoma-market-is-likely-to-grow-at-a-modest-rate-owing-to-rising-prevalence-and-the-anticipated-launch-of-novel-therapies-by-major-pharmaceutical-companies_546812.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-546812","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=546812"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546812\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=546812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=546812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=546812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}